10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10x Genomics, Inc.

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

10x Genomics

 #Singlecellspatial lets researchers like Dr. Nick Banovich take their research to the next level by offering gross tissue morphology and single-molecule RNA transcript detection at subcellular resolution on a single section. Hear why he was excited to get his hands on Xenium #InSitu in a quick clip below, then watch the full webinar for more! https://lnkd.in/gurVFX-r

We just wrapped up an amazing, empowering week in Palm Springs with our global commercial team! 🌴🎉 The week unfolded with a focus on innovation and professional development featuring keynote speakers and breakout sessions. Did we mention we also had a ton of fun?! We had an array of team-building activities, from early morning sessions of pickleball and yoga, to carnival booth games, to an "Old Hollywood''-themed awards celebration and dinner. A HUGE thanks to our amazing commercial team who brought collaborative energy, shared powerful insights, and strengthened professional relationships. 🙌 

Hippos eat more than 80 lbs of food a day to support their massive size. Organs use the Hippo pathway—which controls organ size by regulating cell proliferation and apoptosis. #Cancer often takes advantage of the Hippo pathway to boost tumor growth, but therapeutically targeting it is challenging. Check out this study to see how Genentech researchers used #singlecell methods to measure the efficacy of their small molecule inhibitor candidate! 

Heart defects are the leading cause of fetal death, but, historically, research on this important subject has been difficult for a number of reasons, including the inaccessibility of human embryonic samples and the limitations of in vitro models. However, in honor of #AmericanHeartMonth, we’re highlighting a recent paper that uncovered new insights into underlying defects in the developing human heart, using our #singlecell Flex assay to generate compartment-specific, in vivo–like gene expression profiles. Read the paper!

What do mini-kidneys, tiny tumors, and little livers have in common? They were highlighted in one of our top blogs from 2023! Read the blog to learn how scientists are using #organoid models and high-resolution #singlecell analysis to identify druggable disease pathways, screen drugs, model drug metabolism, and explore patient-specific therapeutic responses! 

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-18.76M -	-112.48M 499.54%	-31.25M 72.22%	-542.73M 1,636.68%	-58.22M 89.27%	-166M 185.11%	-255.10M 53.67%
depreciation and amortization	4.30M -	3.90M 9.29%	7.07M 80.95%	19.02M 169.19%	28.25M 48.54%	33.01M 16.82%	43.62M 32.15%
deferred income tax		251K -	614K 144.62%	1.55M 152.44%			-262.95M -
stock based compensation	1.66M -	2.66M 60.02%	13.33M 401.62%	48.63M 264.70%	95.96M 97.35%	136.85M 42.61%	166.95M 22.00%
change in working capital	1.95M -	28.02M 1,338.14%	44.76M 59.79%	-50.38M 212.55%	-87.44M 73.57%	-39.42M 54.92%	17.34M 144.00%
accounts receivables	-5.13M -	-14.75M 187.41%	-5.28M 64.17%	-17.85M 237.76%	-34.04M 90.74%	-18.95M 44.34%	-10.61M 43.99%
inventory	-2.00M -	-3.73M 87.07%	-6.70M 79.50%	-14.60M 117.96%	-30.13M 106.37%	-21.19M 29.67%	7.87M 137.14%
accounts payables	3.03M -	2.59M 14.73%	4.90M 89.45%	-7.77M 258.54%	11.08M 242.65%	5.86M 47.15%	-6.02M 202.71%
other working capital	6.04M -	43.91M 626.94%	51.85M 18.08%	-10.16M 119.60%	-34.36M 238.05%	-5.13M 85.05%	26.10M 608.32%
other non cash items	149K -	1.25M 736.91%	101K 91.90%	306.02M 302,887.13%	79K 99.97%	1.96M 2,377.22%	274.94M 13,948.90%
net cash provided by operating activities	-10.70M -	-76.41M 614.17%	34.63M 145.32%	-217.90M 729.27%	-21.37M 90.19%	-33.61M 57.24%	-15.20M 54.78%
investments in property plant and equipment	-3.76M -	-6.71M 78.62%	-42.77M 537.46%	-38.39M 10.23%	-101.28M 163.79%	-131.66M 30.00%	-49.52M 62.39%
acquisitions net					-5.45M -	-4M 26.62%
purchases of investments						-282.87M -
sales maturities of investments						67.64M -	183.02M 170.55%
other investing activites							-1 -
net cash used for investing activites	-3.76M -	-6.71M 78.62%	-42.77M 537.46%	-38.39M 10.23%	-106.73M 177.98%	-350.89M 228.76%	133.49M 138.04%
debt repayment	-393K -	-773K 96.69%	-11M 1,323.03%	-31.26M 184.15%	-5.03M 83.91%	-5.41M 7.58%	-5.81M 7.49%
common stock issued		1.80M -	410.82M 22,748.94%	482.27M 17.39%	40.33M 91.64%	21.23M 47.36%	19.48M 8.21%
common stock repurchased	-80K -
dividends paid
other financing activites	21.06M -	104.34M 395.55%	14.77M 85.85%	17.89M 21.19%
net cash used provided by financing activities	20.58M -	105.37M 411.91%	414.59M 293.47%	468.91M 13.10%	35.30M 92.47%	15.82M 55.19%	13.67M 13.58%
effect of forex changes on cash	-14K -	-18K 28.57%	-45K 150%	-463K 928.89%	234K 150.54%	-44K 118.80%	-33K 25%
net change in cash	6.11M -	22.23M 263.61%	406.40M 1,728.10%	212.15M 47.80%	-92.57M 143.63%	-368.72M 298.31%	136.91M 137.13%
cash at beginning of period	41.74M -	47.86M 14.65%	70.09M 46.45%	476.49M 579.85%	688.64M 44.52%	596.07M 13.44%	222.38M 62.69%
cash at end of period	47.86M -	70.09M 46.45%	476.49M 579.85%	688.64M 44.52%	596.07M 13.44%	227.35M 61.86%	359.28M 58.03%
operating cash flow	-10.70M -	-76.41M 614.17%	34.63M 145.32%	-217.90M 729.27%	-21.37M 90.19%	-33.61M 57.24%	-15.20M 54.78%
capital expenditure	-3.76M -	-6.71M 78.62%	-42.77M 537.46%	-38.39M 10.23%	-101.28M 163.79%	-131.66M 30.00%	-49.52M 62.39%
free cash flow	-14.46M -	-83.12M 475.01%	-8.14M 90.21%	-256.29M 3,048.55%	-122.65M 52.14%	-165.27M 34.75%	-64.72M 60.84%

COM:10XGENOMICS

10x Genomics, Inc.

Last Close

13.29

22/11 21:00

Market Cap

1.88B

Beta: -

Volume Today

4.50M

Avg: -

Preview